Companies ›Consumer Non Cyclicals ›APCO.BK

APCO.BK — SET (Bangkok) Personal Products

Asian Phytoceuticals PCL

$2,66

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

3,42 %

Op margin

30,6 %

ROE

2,6 %

Net margin

30,1 %

Debt / equity

0,05

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

Asian Phytoceuticals PCL develops, produces, and distributes personal care products, primarily leveraging natural and herbal ingredients to serve the consumer non-cyclical market.

Business. Asian Phytoceuticals PCL (APCO.BK) is a personal products company operating within the Consumer Non-Cyclicals sector. The firm generates revenue through the sale of personal care items and is headquartered in Thailand. It is primarily listed on the Stock Exchange of Thailand (SET). Specific details regarding operating segments and geographic revenue mix are not disclosed.

Classification92 %

SectorConsumer Non-Cyclicals

Business sectorPersonal & Household Products & Services

IndustryPersonal Products

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership

—

not yet wired

Profitability→

2,6 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning APCO.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples · THIS SECTOR−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to APCO.BK. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Asian Phytoceuticals PCL (APCO.BK) is a personal products company operating within the Consumer Non-Cyclicals sector. The firm generates revenue through the sale of personal care items and is headquartered in Thailand. It is primarily listed on the Stock Exchange of Thailand (SET). Specific details regarding operating segments and geographic revenue mix are not disclosed.

Classification92 %

SectorConsumer Non-Cyclicals

Business sectorPersonal & Household Products & Services

IndustryPersonal Products

AI synthesis

GENERATED

Asian Phytoceuticals PCL maintains a strong liquidity position, with a current ratio of 6.33, indicating that the company has sufficient short-term assets to cover its liabilities. The company's debt-to-equity ratio is 0.05, suggesting a conservative capital structure with minimal reliance on debt financing. However, the risk assessment notes that net cash is negative after subtracting total debt, signaling potential liquidity constraints.

In terms of profitability, the company's return on equity (ROE) is 2.63%, and return on assets (ROA) is 2.28%, both of which are below the typical thresholds for high-performing firms in the personal care products industry. These figures suggest that the company is generating modest returns relative to its equity and asset base, which may indicate inefficiencies or a competitive disadvantage in the market.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification could expose the company to regional economic downturns or regulatory changes that affect its primary market.

Looking ahead, the company's growth trajectory appears to be modest, with no significant revenue growth or decline reported in the most recent financial period. The absence of capital expenditures, as indicated by a capital expenditure of -226,800 THB, suggests that the company is not currently investing in new projects or infrastructure, which could limit its long-term growth potential.

The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's liquidity risk is primarily due to the negative net cash position after accounting for total debt. The dilution risk is low, as there is no indication of share issuance or dilution pressure in the near term.

Recent events, as disclosed in the company's financial filings, do not indicate any material changes in operations or strategy. The company continues to focus on its core personal care product line, with no new product launches or strategic acquisitions reported in the latest financial period.

Key takeaways

Asian Phytoceuticals PCL has a strong liquidity position with a current ratio of 6.33.
The company's ROE and ROA are below typical industry benchmarks, indicating modest profitability.
Revenue is concentrated in a single business segment with no significant geographic diversification.
The company is not currently investing in new projects or infrastructure, as indicated by minimal capital expenditures.
The company faces a medium liquidity risk due to a negative net cash position after total debt.

Bull / Bear case

Generated · model-assisted

BULL CASE · 3

Free cash flow surged 159.7% year-over-year to THB 20.2 million, demonstrating strong cash generation recovery.

With a debt-to-equity ratio of 0.05, the firm maintains a conservative leverage profile well below the cohort median.

Cash conversion of 1.24 exceeds the cohort median of 0.97, indicating efficient translation of earnings into cash.

BEAR CASE · 2

Net income fell 5.2% annually over four years, signaling a long-term deterioration in profitability trends.

The company faces medium liquidity risk, which could constrain operational flexibility or dividend sustainability.

In focus — financials by report

Annual

ANNUALFiled 2014-02-18

FY 2014 · Full-year highlights

Revenue THB 223.4M; Operating income THB 73.8M.

RevenueTHB 223.4M

Operating incomeTHB 73.8M

Net incomeTHB 68.7M

Free cash flowTHB 22.5M

EPS—

Operating cash flowTHB 84.4M

Financials

Income statement

RevenueTHB 223.4M

Gross profitTHB 177.1M

Operating incomeTHB 73.8M

Net incomeTHB 68.7M

Margins

Gross margin79.3%

Operating margin33.1%

Net margin30.8%

FCF margin10.1%

Balance sheet

Total assetsTHB 680.5M

Total liabilitiesTHB 85.5M

Total equityTHB 595.0M

Cash & equivalents—

Long-term debtTHB 34.2M

Cash flow

Operating cash flowTHB 84.4M

CapEx-THB 1.2M

Free cash flowTHB 22.5M

SBC—

P&L flow · revenue → net income

Highlights

▍Revenue THB 223.4M
▍Operating income THB 73.8M
▍Net margin 30.8%

Valuation FY

Market price

$2,66

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

$625.9M

Net cashⓘ

-$32.3M

Current ratioⓘ

6.3

Debt / equityⓘ

0.1

ROAⓘ

2.3%

ROEⓘ

2.6%

Cash conversionⓘ

124.0%

CapEx / revenueⓘ

-0.4%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskMedium

Filing-based flags

Net cash is negative after subtracting total debt.

Benchmarks vs cohort

Op Margin30,6 %Best in class

Net Margin30,1 %Best in class

ROE2,6 %Below median

Capex / Rev-0,4 %Above P75

D/E0,05Above median

Cash Conv1,24Above median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Capex To Revenue
capital_expenditure / revenue
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Cash Conversion Ratio
operating_cash_flow / net_income

Source documents

Asian Phytoceuticals PCL Market data — financials · 2026-05-27

Ownership & reference

Leadership

Phichet ViriyachitraChief Executive Officer, Executive Director

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

APCO.BKCanonical

SET (Bangkok) · USD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskMedium

Net cash is negative after subtracting total debt.

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

2014-02-18 20:15 UTCEARNINGSAnnual results — FY 2014 Revenue THB 223.4M · Net THB 68.7M

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Leadership

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread